Nature Medicine

Article	Citations
Post-acute COVID-19 syndrome	3278
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	3226
A global survey of potential acceptance of a COVID-19 vaccine	1866
Attributes and predictors of long COVID	1691
Long-term cardiovascular outcomes of COVID-19	1222
AI in health and medicine	967
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	877
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	840
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	796
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	717
Large language models in medicine	710
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	638
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	595
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	557
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	556
Targeting metastatic cancer	553
Symptoms and risk factors for long COVID in non-hospitalized adults	552
SARS-CoV-2 infection of the oral cavity and saliva	540
Long COVID after breakthrough SARS-CoV-2 infection	533
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	532
Biomarkers for neurodegenerative diseases	517
Immune determinants of COVID-19 disease presentation and severity	502
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	500
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	499
Single-cell multi-omics analysis of the immune response in COVID-19	496

Toward personalized treatment approaches for non-small-cell lung cancer	487
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	483
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	477
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	469
Long COVID in a prospective cohort of home-isolated patients	464
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	461
Deep learning in histopathology: the path to the clinic	461
Understanding COVID-19 vaccine hesitancy	458
Looking beyond COVID-19 vaccine phase 3 trials	456
Intratumoral heterogeneity in cancer progression and response to immunotherapy	452
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	443
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	432
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	428
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	423
Cellular senescence and senolytics: the path to the clinic	416
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	396
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	396
Brown adipose tissue is associated with cardiometabolic health	390
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	387
Partial recovery of visual function in a blind patient after optogenetic therapy	387
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	386
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	383
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	382
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	379
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	379
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	371
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	371
Federated learning for predicting clinical outcomes in patients with COVID-19	361
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	360
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	350
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	348
Multimodal biomedical AI	344
Wearable sensor data and self-reported symptoms for COVID-19 detection	343
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	342
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	338
Modeling COVID-19 scenarios for the United States	338
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	332
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	329
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	328
Sixteen novel lineages of SARS-CoV-2 in South Africa	323
Acute and postacute sequelae associated with SARS-CoV-2 reinfection	321
Unexplained post-acute infection syndromes	313
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	311
SARS-CoV-2 variants of concern are emerging in India	308
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	307
Long-term neurologic outcomes of COVID-19	302
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	302
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	297
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial	295
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	294

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	292
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries	291
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	290
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	289
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster	288
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	286
Targeting the HIF2–VEGF axis in renal cell carcinoma	283
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	278
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	278
Microglial activation and tau propagate jointly across Braak stages	277
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial	271
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	270
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures	269
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	267
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	267
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	265
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	264
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	264
Closed-loop neuromodulation in an individual with treatment-resistant depression	264
A roadmap to increase diversity in genomic studies	259
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial	252
Vaccine development for emerging infectious diseases	251
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	251
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	250
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	249
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	244
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	241
The distribution of cellular turnover in the human body	240
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	240
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	239
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	238
A guide to immunotherapy for COVID-19	238
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer	235
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial	233
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial	232
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	229
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	229
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	228
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge	227
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	225
Heat-related mortality in Europe during the summer of 2022	225
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma	224
Misinformation: susceptibility, spread, and interventions to immunize the public	224
Increased global integration in the brain after psilocybin therapy for depression	224
Targeting the gut and tumor microbiota in cancer	221
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	221
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	220
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis	219
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	219
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	217
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial	215
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma	215
The next generation of evidence-based medicine	214
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	214
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial	214
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	212
The landscape of mRNA nanomedicine	212
Reporting guidelines for human microbiome research: the STORMS checklist	212
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	210
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk	209
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1	208
Crowding and the shape of COVID-19 epidemics	207
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	206
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease	205
An integrated cell atlas of the lung in health and disease	203
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial	203
COVID-19 and resilience of healthcare systems in ten countries	200
Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial	200
Modeling transmission of SARS-CoV-2 Omicron in China	200
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor	199
How COVID-19 shaped mental health: from infection to pandemic effects	195
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma	195
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy	193
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial	193
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer	193
Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI	191
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers	189
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland	188
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease	188
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology	188

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis	186
Delayed production of neutralizing antibodies correlates with fatal COVID-19	186
The Global Burden of Disease Study at 30 years	185
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021	184
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2	182
Delivering precision oncology to patients with cancer	180
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis	178
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer	176
COVID-19 dynamics after a national immunization program in Israel	176
A survey of COVID-19 vaccine acceptance across 23 countries in 2022	175
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial	175
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium	174
A correlate of protection for SARS-CoV-2 vaccines is urgently needed	173
Redefining critical illness	173
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma	173
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors	172
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis	170
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis	170
AI in medicine must be explainable	169
Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality	168
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma	165
Distinction of lymphoid and myeloid clonal hematopoiesis	165
Performance of plasma phosphorylated tau 181 and 217 in the community	164
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma	164
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines	163
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy	162
An algorithmic approach to reducing unexplained pain disparities in underserved populations	161
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline	160
Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19	159
The future of early cancer detection	156
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial	156
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring	155
Large-scale genome-wide association study of coronary artery disease in genetically diverse populations	155
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases	154
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial	154
Wearable sensors enable personalized predictions of clinical laboratory measurements	153
Priorities for cancer research in low- and middle-income countries: a global perspective	153
Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma	153
IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies	152
Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19	152
Engineered cellular immunotherapies in cancer and beyond	152
Metabolomic profiles predict individual multidisease outcomes	151
Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants	150
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial	150
Modeling human adaptive immune responses with tonsil organoids	149
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER	149
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial	148
Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease	148
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial	148
Comorbidities, multimorbidity and COVID-19	148
Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial	148
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19	147
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial	147
An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease	146
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)	146
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy	144
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer	143
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave	142
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing	142
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia	142
Postacute sequelae of COVID-19 at 2 years	141
Microbiome and metabolome features of the cardiometabolic disease spectrum	141
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial	140
State-dependent responses to intracranial brain stimulation in a patient with depression	140
Humoral signatures of protective and pathological SARS-CoV-2 infection in children	140
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial	139
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial	139
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial	138
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results	138
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication	136
A neuroimaging biomarker for sustained experimental and clinical pain	136
Will ChatGPT transform healthcare?	135
Challenges and opportunities in NASH drug development	135
Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake	133
Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome	133
Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals	132
Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases	131
AlphaFold heralds a data-driven revolution in biology and medicine	130
The effects of tobacco control policies on global smoking prevalence	130
Real-world effectiveness of a single dose of mpox vaccine in males	129
Integrative microbiomics in bronchiectasis exacerbations	129
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy	127
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial	127
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial	127
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis	127
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials	127
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial	125
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial	124
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial	123
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort	122
Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection	121
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials	121
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	120
Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis	119
Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition	119